{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T11:04:39Z","timestamp":1777460679074,"version":"3.51.4"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T00:00:00Z","timestamp":1692921600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T00:00:00Z","timestamp":1692921600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["215490\/Z\/19\/Z"],"award-info":[{"award-number":["215490\/Z\/19\/Z"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["215490\/Z\/19\/Z"],"award-info":[{"award-number":["215490\/Z\/19\/Z"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["215490\/Z\/19\/Z"],"award-info":[{"award-number":["215490\/Z\/19\/Z"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["215490\/Z\/19\/Z"],"award-info":[{"award-number":["215490\/Z\/19\/Z"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["215490\/Z\/19\/Z"],"award-info":[{"award-number":["215490\/Z\/19\/Z"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["215490\/Z\/19\/Z"],"award-info":[{"award-number":["215490\/Z\/19\/Z"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["215490\/Z\/19\/Z"],"award-info":[{"award-number":["215490\/Z\/19\/Z"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Group A Streptococcus causes a wide range of diseases from relatively mild infections including pharyngitis to more severe illnesses such as invasive diseases and rheumatic heart disease (RHD). Our aim is to estimate the cost-effectiveness of a hypothetical Strep A vaccine on multiple disease manifestations at the global-level. Cost-effectiveness analyses were carried out by building on the potential epidemiological impact of vaccines that align with the WHO\u2019s Preferred Product Characteristics for Strep A vaccines. Maximum vaccination costs for a cost-effective vaccination strategy were estimated at the thresholds of 1XGDP per capita and health opportunity costs. The maximum cost per fully vaccinated person for Strep A vaccination to be cost-effective was $385\u2013$489 in high-income countries, $213\u2013$312 in upper-income-income countries, $74\u2013$132 in lower-middle-income countries, and $37\u2013$69 in low-income countries for routine vaccination at birth and 5 years of age respectively. While the threshold costs are sensitive to vaccine characteristics such as efficacy, and waning immunity, a cost-effective Strep A vaccine will lower morbidity and mortality burden in all income settings.<\/jats:p>","DOI":"10.1038\/s41541-023-00718-7","type":"journal-article","created":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T13:02:55Z","timestamp":1692968575000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["The potential global cost-effectiveness of prospective Strep A vaccines and associated implementation efforts"],"prefix":"10.1038","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1038-8948","authenticated-orcid":false,"given":"Jung-Seok","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0596-8072","authenticated-orcid":false,"given":"Vittal","family":"Mogasale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-8604-8884","authenticated-orcid":false,"given":"Sol","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1321-9605","authenticated-orcid":false,"given":"Jeffrey","family":"Cannon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6302-506X","authenticated-orcid":false,"given":"Fiona","family":"Giannini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0563-1576","authenticated-orcid":false,"given":"Kaja","family":"Abbas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6462-5101","authenticated-orcid":false,"given":"Jean-Louis","family":"Excler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0461-6438","authenticated-orcid":false,"given":"Jerome H.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,8,25]]},"reference":[{"key":"718_CR1","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/S1473-3099(05)70267-X","volume":"5","author":"JR Carapetis","year":"2005","unstructured":"Carapetis, J. R., Steer, A. C., Mulholland, E. K. & Weber, M. The global burden of group A streptococcal diseases. Lancet Infect. Dis. 5, 685\u2013694 (2005).","journal-title":"Lancet Infect. Dis."},{"key":"718_CR2","unstructured":"Sims Sanyahumbi, A., Colquhoun, S., Wyber, R. & Carapetis, J. R. In Streptococcus pyogenes : Basic Biology to Clinical Manifestations (eds J. J. Ferretti, D. L. Stevens, & V. A. Fischetti) (2016)."},{"key":"718_CR3","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1056\/NEJMoa1603693","volume":"377","author":"DA Watkins","year":"2017","unstructured":"Watkins, D. A. et al. Global, regional, and national burden of rheumatic heart disease, 1990\u20132015. N. Engl. J. Med. 377, 713\u2013722 (2017).","journal-title":"N. Engl. J. Med."},{"key":"718_CR4","doi-asserted-by":"publisher","unstructured":"Hand, R. M., Snelling, T. L. & Carapetis, J. R. Group A Streptococcus. Hunter\u2019s Tropical Medicine and Emerging Infectious Diseases, 429-438. https:\/\/doi.org\/10.1016\/B978-0-323-55512-8.00040-5 (2020).","DOI":"10.1016\/B978-0-323-55512-8.00040-5"},{"key":"718_CR5","doi-asserted-by":"crossref","unstructured":"Ralph, A. P. & Carapetis, J. R. Vol. 368 1\u201327 (2013).","DOI":"10.1007\/82_2012_280"},{"key":"718_CR6","doi-asserted-by":"publisher","first-page":"e557","DOI":"10.1542\/peds.2009-2648","volume":"126","author":"N Shaikh","year":"2010","unstructured":"Shaikh, N., Leonard, E. & Martin, J. M. Prevalence of Streptococcal Pharyngitis and Streptococcal carriage in children: a meta-analysis. Pediatrics 126, e557\u2013e564 (2010).","journal-title":"Pediatrics"},{"key":"718_CR7","doi-asserted-by":"publisher","first-page":"101458","DOI":"10.1016\/j.eclinm.2022.101458","volume":"48","author":"KM Miller","year":"2022","unstructured":"Miller, K. M. et al. The global burden of sore throat and group A Streptococcus pharyngitis: a systematic review and meta-analysis. EClinicalMedicine 48, 101458 (2022).","journal-title":"EClinicalMedicine"},{"key":"718_CR8","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1111\/j.1365-3156.2010.02670.x","volume":"16","author":"SJ Jackson","year":"2011","unstructured":"Jackson, S. J., Steer, A. C. & Campbell, H. Systematic Review: estimation of global burden of non-suppurative sequelae of upper respiratory tract infection: rheumatic fever and post-streptococcal glomerulonephritis: Global burden of rheumatic fever and post-streptococcal glomerulonephritis. Tropical Med. Int. health 16, 2\u201311 (2011).","journal-title":"Tropical Med. Int. health"},{"key":"718_CR9","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1093\/cid\/ciy1143","volume":"69","author":"J Vekemans","year":"2019","unstructured":"Vekemans, J. et al. The Path to Group A Streptococcus Vaccines: World Health Organization Research and Development Technology Roadmap and Preferred Product Characteristics. Clin. Infect. Dis. 69, 877\u2013883 (2019).","journal-title":"Clin. Infect. Dis."},{"key":"718_CR10","doi-asserted-by":"crossref","unstructured":"Lee, J.-S., Kim, S., Excler, J.-L., Kim, J. & Mogasale, V. J. W. O. R. Existing cost-effectiveness analyses for diseases caused by Group A Streptococcus: A systematic review to guide future research. 6, 211 (2021).","DOI":"10.12688\/wellcomeopenres.17116.1"},{"key":"718_CR11","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1586\/14737167.2013.852470","volume":"13","author":"RA Manji","year":"2013","unstructured":"Manji, R. A. et al. Cost-effectiveness analysis of rheumatic heart disease prevention strategies. Expert Rev. pharmacoeconomics outcomes Res. 13, 715\u2013724 (2013).","journal-title":"Expert Rev. pharmacoeconomics outcomes Res."},{"key":"718_CR12","doi-asserted-by":"publisher","first-page":"2865","DOI":"10.1016\/j.vaccine.2016.02.078","volume":"34","author":"BK Giersing","year":"2016","unstructured":"Giersing, B. K. et al. Report from the World Health Organization\u2019s product development for Vaccines Advisory Committee (PDVAC) meeting, Geneva, 7\u20139th Sep 2015. Vaccine 34, 2865\u20132869 (2016).","journal-title":"Vaccine"},{"key":"718_CR13","doi-asserted-by":"publisher","first-page":"7315","DOI":"10.1016\/j.vaccine.2016.10.090","volume":"37","author":"BK Giersing","year":"2017","unstructured":"Giersing, B. K., Vekemans, J., Nava, S., Kaslow, D. C. & Moorthy, V. Report from the World Health Organization\u2019s third Product Development for Vaccines Advisory Committee (PDVAC) meeting, Geneva, 8\u201310th June 2016. Vaccine 37, 7315\u20137327 (2017).","journal-title":"Vaccine"},{"key":"718_CR14","unstructured":"CDC, U. 2019 AR Threats Report, https:\/\/www.cdc.gov\/drugresistance\/biggest-threats.html (2019)."},{"key":"718_CR15","doi-asserted-by":"publisher","unstructured":"Lewnard, J. A., King, L. M., Fleming-Dutra, K. E., Link-Gelles, R. & Van Beneden, C. A. Incidence of pharyngitis, sinusitis, acute otitis media, and outpatient antibiotic prescribing preventable by vaccination against group A Streptococcus in the United States. Clin. Infect Dis. https:\/\/doi.org\/10.1093\/cid\/ciaa529 (2020).","DOI":"10.1093\/cid\/ciaa529"},{"key":"718_CR16","doi-asserted-by":"publisher","unstructured":"Asturias, E. J. et al. Safety of Streptococcus pyogenes vaccines: anticipating and overcoming challenges for clinical trials and post marketing monitoring. Clin Infect Dis. https:\/\/doi.org\/10.1093\/cid\/ciad311 (2023).","DOI":"10.1093\/cid\/ciad311"},{"key":"718_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-023-00668-0","volume":"8","author":"F Giannini","year":"2023","unstructured":"Giannini, F. et al. Modeling the potential health impact of prospective Strep A vaccines. NPJ Vaccines 8, 90 (2023).","journal-title":"NPJ Vaccines"},{"key":"718_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-023-00659-1","volume":"8","author":"JS Lee","year":"2023","unstructured":"Lee, J. S., Kim, S., Excler, J. L., Kim, J. H. & Mogasale, V. Global economic burden per episode for multiple diseases caused by group A Streptococcus. NPJ Vaccines 8, 69 (2023).","journal-title":"NPJ Vaccines"},{"key":"718_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-020-1507-2","volume":"18","author":"M Jit","year":"2020","unstructured":"Jit, M. et al. Quantifying the economic cost of antibiotic resistance and the impact of related interventions: rapid methodological review, conceptual framework and recommendations for future studies. BMC Med. 18, 38 (2020).","journal-title":"BMC Med"},{"key":"718_CR20","doi-asserted-by":"publisher","first-page":"12911","DOI":"10.1073\/pnas.1717161115","volume":"115","author":"JP Sevilla","year":"2018","unstructured":"Sevilla, J. P., Bloom, D. E., Cadarette, D., Jit, M. & Lipsitch, M. Toward economic evaluation of the value of vaccines and other health technologies in addressing AMR. Proc. Natl Acad. Sci. USA 115, 12911\u201312919 (2018).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"718_CR21","doi-asserted-by":"publisher","first-page":"6591","DOI":"10.1016\/j.vaccine.2017.09.053","volume":"35","author":"C Clift","year":"2017","unstructured":"Clift, C. & Salisbury, D. M. Enhancing the role of vaccines in combatting antimicrobial resistance. Vaccine 35, 6591\u20136593 (2017).","journal-title":"Vaccine"},{"key":"718_CR22","unstructured":"World Health Organization. WHO preferred product characteristics for group A streptococcus vaccines. (World Health Organization, Geneva, 2018)."},{"key":"718_CR23","unstructured":"World Health Organization. WHO guide for standardization of economic evaluations of immunization programmes. (World Health Organization, 2019)."},{"key":"718_CR24","doi-asserted-by":"publisher","first-page":"e1002181","DOI":"10.1371\/journal.pmed.1002181","volume":"13","author":"S Flasche","year":"2016","unstructured":"Flasche, S. et al. The long-term safety, public health impact, and cost-effectiveness of routine vaccination with a recombinant, live-attenuated dengue vaccine (Dengvaxia): a model comparison study. PLoS Med. 13, e1002181 (2016).","journal-title":"PLoS Med."},{"key":"718_CR25","doi-asserted-by":"publisher","first-page":"2346","DOI":"10.1016\/j.vaccine.2018.03.002","volume":"36","author":"JS Lee","year":"2018","unstructured":"Lee, J. S., Lourenco, J., Gupta, S. & Farlow, A. A multi-country study of dengue vaccination strategies with Dengvaxia and a future vaccine candidate in three dengue-endemic countries: Vietnam, Thailand, and Colombia. Vaccine 36, 2346\u20132355 (2018).","journal-title":"Vaccine"},{"key":"718_CR26","doi-asserted-by":"publisher","first-page":"118","DOI":"10.2471\/BLT.14.138206","volume":"93","author":"E Marseille","year":"2015","unstructured":"Marseille, E., Larson, B., Kazi, D. S., Kahn, J. G. & Rosen, S. Thresholds for the cost-effectiveness of interventions: alternative approaches. Bull. World Health Organ 93, 118\u2013124 (2015).","journal-title":"Bull. World Health Organ"},{"key":"718_CR27","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/s40273-014-0162-x","volume":"32","author":"AT Newall","year":"2014","unstructured":"Newall, A. T., Jit, M. & Hutubessy, R. Are current cost-effectiveness thresholds for low- and middle-income countries useful? Examples from the world of vaccines. Pharmacoeconomics 32, 525\u2013531 (2014).","journal-title":"Pharmacoeconomics"},{"key":"718_CR28","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1080\/14737167.2020.1812387","volume":"21","author":"J Ochalek","year":"2021","unstructured":"Ochalek, J., Claxton, K., Lomas, J. & Thompson, K. M. Valuing health outcomes: developing better defaults based on health opportunity costs. Expert Rev. Pharmacoeconomics Outcomes Res. 21, 729\u2013736 (2021).","journal-title":"Expert Rev. Pharmacoeconomics Outcomes Res."}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-023-00718-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-023-00718-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-023-00718-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T23:06:47Z","timestamp":1700521607000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-023-00718-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,25]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["718"],"URL":"https:\/\/doi.org\/10.1038\/s41541-023-00718-7","relation":{},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,25]]},"assertion":[{"value":"12 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"128"}}